MDGL · Healthcare · $11.6B
After-hours $499.710.00%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“레즈디프라(Rezdiffra)가 출시 2년 만에 연간 매출 1조 5천억 원(11억 달러)을 돌파하며 '블록버스터' 반열에 올랐어요.”
In the company's words · 2026 1분기 earnings call